Omeros Corporation - Product Pipeline Review - 2014

Published: Sep, 2014 | Pages: 132 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Omeros Corporation - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Omeros Corporation - Product Pipeline Review - 2014', provides an overview of the Omeros Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Omeros Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Omeros Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Omeros Corporation's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Omeros Corporation's pipeline products

Reasons to buy

- Evaluate Omeros Corporation's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Omeros Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Omeros Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Omeros Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Omeros Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Omeros Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Omeros Corporation Snapshot 6
Omeros Corporation Overview 6
Key Information 6
Key Facts 6
Omeros Corporation - Research and Development Overview 7
Key Therapeutic Areas 7
Omeros Corporation - Pipeline Review 14
Pipeline Products by Stage of Development 14
Pipeline Products - Monotherapy 15
Pipeline Products - Combination Treatment Modalities 16
Omeros Corporation - Pipeline Products Glance 17
Omeros Corporation - Late Stage Pipeline Products 17
Omeros Corporation - Clinical Stage Pipeline Products 19
Omeros Corporation - Early Stage Pipeline Products 21
Omeros Corporation - Drug Profiles 25
(ketorolac tromethamine + phenylephrine) 25
(ketoprofen + amitriptyline + oxymetazoline) 27
OMS-405 29
OMS-721 30
OMS-824 32
(ketoprofen + nifedipine) 33
Monoclonal Antibodies to Antagonize FN14 for Cancer 35
Monoclonal Antibodies to Antagonize FZD10 for Cancer 37
Monoclonal Antibodies to Antagonize Tie2 for Cancer 39
Monoclonal Antibodies to Antagonize VEGFR2 for Cancer 41
Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications 43
Monoclonal Antibodies to Inhibit TROP2 for Cancer 45
OMS-527 47
OMS-616 49
Small Molecule Target GPR176 for Atherosclerosis 51
Small Molecule to Antagonize GPR101 for Appetite Disorder 52
Small Molecule to Antagonize GPR12 for Obesity, Cognitive Impairments and Motor Disorders 53
Small Molecule to Antagonize GPR139 for Motor Control 54
Small Molecule to Antagonize GPR15 for Rheumatoid Arthritis and HIV-Mediated Enteropathy 55
Small Molecule to Antagonize GPR161 for Metastatic Epithelial Cancers, Congenital Cataracts and Birth Defects of the Brain and Spinal Cord 56
Small Molecule to Antagonize GPR17 for Central Nervous System Disorders 57
Small Molecule to Antagonize GPR173 for Obesity and Schizophrenia 58
Small Molecule to Antagonize GPR182 for Pancreatic Cancer 59
Small Molecule to Antagonize GPR19 for Metastatic Melanoma 60
Small Molecule to Antagonize GPR20 for Gastrointestinal Disorders 61
Small Molecule to Antagonize GPR27 for Obesity and Schizophrenia 62
Small Molecule To Antagonize GPR31 for Anxiety Disorders 63
Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes 64
Small Molecule To Antagonize GPR78 for Bipolar Disorder and Schizophrenia 65
Small Molecule to Antagonize GPR85 for Obesity and Schizophrenia 66
Small Molecule to Antagonize GPR87 for Cancer 67
Small Molecule to antagonize NMUR2 for Pain 68
Small Molecule to Antagonize OPN4 for Circadian Rhythm Irregularities and Sleep Disorders 69
Small Molecule to Antagonize P2Y8 for Acute Lymphoblastic Leukemia 70
Small Molecule to Inhibit CCRL2 for Rheumatoid Arthritis and Immune Disorders 71
Small Molecule to Target GPR132 for Atherosclerosis 72
Small Molecule to Target GPR135 for Undisclosed Indication 73
Small Molecule to Target GPR141 for Respiratory and Immune Disorders 74
Small Molecule to Target GPR150 for Ovarian Cancer 75
Small Molecule to Target GPR151 for CNS Diseases 76
Small Molecule to Target GPR153 for Schizophrenia 77
Small Molecule to Target GPR162 for Neuropsychiatric Disorders 78
Small Molecule to Target GPR171 for Hematological Disorders 79
Small Molecule to Target GPR174 for Melanoma and Grave's Disease 80
Small Molecule to Target GPR183 for Humoral Immunity 81
Small Molecule to Target GPR21 for Obesity and Diabetes 82
Small Molecule to Target GPR22 for Osteoarthritis 83
Small Molecule to Target GPR25 for Arterial Stiffness 84
Small Molecule to Target GPR32 for Acute Inflammation 85
Small Molecule to Target GPR37 for Parkinsons Disease 86
Small Molecule to Target GPR37L1 for Hypertension and Cardiac Hypertrophy 87
Small Molecule to Target GPR45 for Undisclosed Indication 88
Small Molecule to Target GPR50 for CNS and Metabolic Disorders 89
Small Molecule to Target GPR52 for Schizophrenia 90
Small Molecule to Target GPR63 for Autism 91
Small Molecule to Target GPR65 for Cancer and Inflammatory Disorders 92
Small Molecule to Target GPR80 for Hepatocellular Carcinoma 93
Small Molecule to Target GPR82 for Appetite Disorders and Body Weight 94
Small Molecule to Target GPR83 for CNS and Immunological Disorders 95
Small Molecule to Target LGR4 for Cancer and Bone Diseases 96
Small Molecule to Target LGR5 for Esophageal Adenocarcinoma 97
Small Molecule to Target LGR6 for Wound Repair and Formation of New Hair Follicles 98
Small Molecule to Target MAS1 for Cognitive Impairments, Blood Pressure Abnormalities and Colon Cancer 99
Small Molecule to Target MRGE for Pain 100
Small Molecule to Target MRGF for Pain 101
Small Molecule to Target OGR1 For Cancer, Bone Diseases and Asthma 102
Small Molecule to Target OPN5 for Undisclosed Indication 103
Small Molecule to Target PTH-1R for Osteoporosis 104
Small Molecules to Inhibit Kinase for Osteoarthritis and Osteoporosis 105
Omeros Corporation - Pipeline Analysis 106
Omeros Corporation - Pipeline Products by Target 106
Omeros Corporation - Pipeline Products by Route of Administration 108
Omeros Corporation - Pipeline Products by Molecule Type 109
Omeros Corporation - Pipeline Products by Mechanism of Action 110
Omeros Corporation - Recent Pipeline Updates 112
Omeros Corporation - Dormant Projects 125
Omeros Corporation - Locations And Subsidiaries 126
Head Office 126
Appendix 127
Methodology 127
Coverage 127
Secondary Research 127
Primary Research 127
Expert Panel Validation 127
Contact Us 128
Disclaimer 128

List of Tables
Omeros Corporation, Key Information 10
Omeros Corporation, Key Facts 10
Omeros Corporation - Pipeline by Indication, 2014 13
Omeros Corporation - Pipeline by Stage of Development, 2014 18
Omeros Corporation - Monotherapy Products in Pipeline, 2014 19
Omeros Corporation - Combination Treatment Modalities in Pipeline, 2014 20
Omeros Corporation - Pre-Registration, 2014 21
Omeros Corporation - Phase III, 2014 22
Omeros Corporation - Phase II, 2014 23
Omeros Corporation - Phase I, 2014 24
Omeros Corporation - Preclinical, 2014 25
Omeros Corporation - Discovery, 2014 28
Omeros Corporation - Pipeline by Target, 2014 111
Omeros Corporation - Pipeline by Route of Administration, 2014 112
Omeros Corporation - Pipeline by Molecule Type, 2014 113
Omeros Corporation - Pipeline Products by Mechanism of Action, 2014 115
Omeros Corporation - Recent Pipeline Updates, 2014 116
Omeros Corporation - Dormant Developmental Projects,2014 129